专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0135942A2 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：WO0135942A2
公开(公告)日：2001-05-25
申请号：PCT/GB0004372
申请日：2000-11-17
申请人： RECKITT & COLMANN PROD LTD , CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
发明人： CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
IPC分类号： A61K9/02 , A61K9/00 , A61K9/08 , A61K9/20 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , A61P25/04 , A61K31/00
CPC分类号： A61K9/0019 , A61K9/0056 , A61K9/006 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , Y10S514/811 , Y10S514/812 , A61K2300/00
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
摘要翻译：以胃肠外单位剂量形式或适合于通过粘膜递送的单位剂量形式的止痛组合物，其包含少于实现疼痛缓解所需的临床剂量的丁丙诺啡和一定量的纳洛酮，使得丁丙诺啡的重量比纳洛酮的范围为12.5:1至27.5:1或纳曲酮或纳美芬的量，使得丁丙诺啡与纳曲酮或纳美芬的重量比在12.5:1至22.5:1的范围内，由此丁丙诺啡的镇痛作用被纳洛酮，纳曲酮或纳美芬的低剂量加强。

2. 发明申请

WO01015699A1 INJECTABLE BUPRENORPHINE MICROPARTICLE COMPOSITIONS AND THEIR USE 审中-公开
标题翻译：可注射的布可乐微量组合物及其用途
公开(公告)号：WO01015699A1
公开(公告)日：2001-03-08
申请号：PCT/US2000/023390
申请日：2000-08-25
IPC分类号： A61K9/14 , A61K9/16 , A61K9/50 , A61K31/485 , A61K47/10 , A61K47/14 , A61K47/32 , A61K47/34 , A61K47/38 , A61P25/30 , A61P25/32 , A61P25/36
CPC分类号： A61K9/0024 , A61K9/1647 , A61K9/5031 , A61K31/485 , Y10S514/811 , Y10S514/812 , Y10S514/951 , Y10S514/952
摘要： An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, a partial opioid agonist or opioid antagonist is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances. Of particular interest are the drugs buprenorphine, methadone and naltrexone.
摘要翻译：在少量残留乙酸乙酯的聚（D，L-丙交酯）赋形剂中提供包含部分阿片样物质激动剂或阿片样物质拮抗剂的注射性缓释部分阿片样物质激动剂或阿片样物质拮抗剂制剂。通过肌内注射组合物，在长时间内以受控的方式释放部分阿片样物质激动剂或阿片样物质拮抗剂。该组合物用于治疗海洛因成瘾者和酗酒者以减少滥用物质的消费。特别感兴趣的是药物丁丙诺啡，美沙酮和纳曲酮。

3. 发明申请

WO98058642A1 ORAL FORMULATIONS FOR CONTROLLED RELEASE OF ALCOHOL DETERRENTS 审中-公开
标题翻译：用于控制释放酒精残留的口服制剂
公开(公告)号：WO98058642A1
公开(公告)日：1998-12-30
申请号：PCT/US1998/013191
申请日：1998-06-25
IPC分类号： A61K9/16 , A61K9/52 , A61K31/275 , A61K31/485 , A61K33/06
CPC分类号： A61K9/1635 , A61K31/275 , A61K31/485 , Y10S514/811 , Y10S977/773 , Y10S977/904 , Y10S977/906
摘要： An oral controlled release dosage form for cyanamide whereby a portion of a cyanamide dose administered to a patient remains transiently partitioned within encapsulating material, thereby retarding metabolism of the total administered cyanamide dose, is described. No investigator has reported the use of dosage forms enabling controlled release of cyanamide. The preparation, when administered to ethanol metabolizing individuals, can elevate blood acetaldehyde to such levels, and for such periods of time, that the individuals will be deterred from future alcohol consumption. The controlled release of cyanamide provides an optimal time-profile of alcohol deterrence specific for individual patients. The formulation avoids the side-effects associated with the relatively high concentrations of cyanamide and cyanamide-metabolites, and the attendant untoward toxic effects, caused by a typical bolus cyanamide dose, thereby attenuating the intensity of the sickness caused by acetaldehyde, and increasing patient compliance with cyanamide therapy.
摘要翻译：描述了一种用于氰胺的口服控制释放剂型，其中给患者施用的一部分氨腈剂量保持短暂地分隔在封装材料内，从而延缓总投与氨酰胺剂量的代谢。没有研究者报告使用可以控制释放氰胺的剂型。当给乙醇代谢个体时，该制剂可以将血液乙醛提高到这样的水平，并且在这样的时间段内，这些个体将被阻止以后的饮酒。氰胺的控制释放提供了针对个体患者的酒精威慑的最佳时间特征。该配方避免了与较高浓度的氨腈和氰胺代谢物相关的副作用，以及由典型的推注青酰胺剂量引起的伴随的不利毒性作用，从而减轻了由乙醛引起的疾病强度，并增加了患者依从性用氨腈治疗。

4. 发明申请

WO9806835A3 Modifying insect cell gylcosylation pathways with baculovirus expression vectors 审中-公开
标题翻译：用杆状病毒表达载体修饰昆虫细胞gylcosylation途径
公开(公告)号：WO9806835A3
公开(公告)日：1998-03-26
申请号：PCT/US9714428
申请日：1997-08-15
申请人： JARVIS DONALD L , TEXAS A & M UNIV SYS
发明人： JARVIS DONALD L
IPC分类号： C07H19/10 , C07H19/20 , C12N9/10 , C12N15/54 , C12N15/866 , C12N15/86 , A01N63/00 , C12N5/06 , C12N7/01 , C12P21/00
CPC分类号： C07H19/10 , A61K31/7048 , C07H19/20 , C12N9/1051 , C12N15/86 , C12N2710/14143 , Y10S514/81 , Y10S514/811
摘要： Alcoholic addiction is treated by administering pyridine nucleotide phosphate derivatives having the formula represented by Formula 1: FORMULA 1 where y can be a second NAD group or an adenosine group and x can be 1, 2, or 3.

5. 发明申请

WO1998006855A1 COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO HEPATOCYTES 审中-公开
标题翻译：用于向细胞核递送核酸的组合物和方法
公开(公告)号：WO1998006855A1
公开(公告)日：1998-02-19
申请号：PCT/US1997014504
申请日：1997-08-15
申请人： THE TEXAS A & M UNIVERSITY SYSTEM , SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH , JARVIS, Donald, L. , LANFORD, Robert
发明人： THE TEXAS A & M UNIVERSITY SYSTEM , SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH
IPC分类号： C12N15/54
CPC分类号： C07H19/10 , A61K31/7048 , C07H19/20 , C12N9/1051 , C12N15/86 , C12N2710/14143 , Y02A50/387 , Y02A50/401 , Y02A50/463 , Y10S514/81 , Y10S514/811
摘要： Disclosed are recombinant baculoviruses that are used to deliver hepatocyte expressable nucleic acid constructs specifically to hepatocytes. Also provided are a variety of recombinant baculovirus vectors which comprise at least one oligosaccharide processing enzyme gene and a hepatocyte expressible nucleic acid segment. The invention also provides methods of using the expression systems and recombinant baculoviruses, particularly in the treatment of liver diseases and/or infections.
摘要翻译：公开了用于将肝细胞可表达的核酸构建体特异性递送至肝细胞的重组杆状病毒。还提供了包含至少一种寡糖加工酶基因和肝细胞可表达的核酸片段的各种重组杆状病毒载体。本发明还提供使用表达系统和重组杆状病毒的方法，特别是用于治疗肝脏疾病和/或感染。

6. 发明申请

WO1996004901A1 COMPOSITION AND METHOD FOR TREATING ANXIETY 审中-公开
标题翻译：用于治疗麻醉的组合物和方法
公开(公告)号：WO1996004901A1
公开(公告)日：1996-02-22
申请号：PCT/US1995010318
申请日：1995-08-14
申请人： ELI LILLY AND COMPANY
发明人： ELI LILLY AND COMPANY , HELTON, David, Reed , KALLMAN, Mary, Jeanne , MONN, James, Allen , SCHOEPP, Darryle, Darwin , TIZZANO, Joseph, Patrick
IPC分类号： A61K31/19
CPC分类号： C07D235/02 , A61K31/00 , A61K31/198 , A61K31/215 , C07C62/38 , C07C229/50 , C07C2602/18 , Y10S514/811 , Y10S514/82
摘要： The present invention provides the use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for the treatment of anxiety and related disorders.
摘要翻译：本发明提供了一种作用于负性偶联的cAMP连接的代谢型谷氨酸受体的激动剂用于治疗焦虑和相关疾病的用途。

7. 发明申请

WO1993016713A2 USE OF MURAMYL PEPTIDE FOR THE TREATMENT OF TOXICITY 审中-公开
标题翻译：使用谷氨酸肽治疗毒性
公开(公告)号：WO1993016713A2
公开(公告)日：1993-09-02
申请号：PCT/GB1993000408
申请日：1993-02-26
申请人： BIOKINE TECHNOLOGIE LIMITED , ASTON, Roger , KOVALEV, Igor Esimovich
发明人： BIOKINE TECHNOLOGIE LIMITED
IPC分类号： A61K37/02
CPC分类号： A61K38/14 , Y10S514/81 , Y10S514/811 , Y10S514/812 , Y10S514/813
摘要： Muramyl peptide compounds are useful in the treatment of toxicity, particularly when this condition results from alcohol, hypnotics or sedatives, anaesthetics, opioids or drug abuse generally. The muramyl peptide compound may be of either of general formulae (I) and (II). Preferred compounds include prototype MDP, muroctasin, MTP-PE, murabutide, t-MDP, N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic acid (GMDP-A).
摘要翻译： Muramyl肽化合物可用于治疗毒性，特别是当这种病症是由酒精，催眠药或镇静剂，麻醉剂，阿片类药物或药物滥用症引起的。胞壁基肽化合物可以是通式（I）和（II）。优选的化合物包括原型MDP，莫曲西星，MTP-PE，murabutide，t-MDP，N-乙酰基 - 葡糖胺基-N-乙酰基 - 胞壁酰基-L-丙氨酰-D-异谷氨酰胺（GMDP）和N-乙酰基 - 葡糖胺基-N-乙酰基 - 月桂酰-L-丙氨酰-D-谷氨酸（GMDP-A）。

8. 发明申请

WO1992016211A1 NEW USE OF DIPHENYLBUTYL-PIPERAZINECARBOXAMIDES IN THE TREATMENT OF SUBSTANCE DISORDERS 审中-公开
标题翻译：二苯乙烯 - 哌嗪甲酰胺在治疗物质障碍方面的新用途
公开(公告)号：WO1992016211A1
公开(公告)日：1992-10-01
申请号：PCT/SE1992000182
申请日：1992-03-23
申请人： KABI PHARMACIA AB , BJÖRK, Anders , CHRISTENSSON, Erik
发明人： KABI PHARMACIA AB
IPC分类号： A61K31/495
CPC分类号： C07D295/215 , A61K31/495 , Y10S514/811 , Y10S514/813
摘要： New use of certain diphenylbutyl-piperazinecarboxamides, especially amperozide, 4-[4,4-bis(4-fluorophenyl)butyl]-N-ethyl-1-piperazinecarboxamide, and salts thereof, in the treatment of substance abuse disorders. More particularly, this treatment relates to the amelioration of withdrawal symptoms and to modifying drug-seeking behaviour.
摘要翻译：某些二苯基丁基 - 哌嗪甲酰胺，特别是安非他酮，4- [4,4-双（4-氟苯基）丁基] -N-乙基-1-哌嗪甲酰胺及其盐的新用途用于治疗物质滥用障碍。更具体地说，这种治疗涉及戒断症状的改善和改善药物寻求行为。

9. 发明申请

WO0135942A9 ANALGESIC COMPOSITIONS CONTAINING BUPRENORPHINE 审中-公开
标题翻译：含有苯丙胺的组合物
公开(公告)号：WO0135942A9
公开(公告)日：2002-11-28
申请号：PCT/GB0004372
申请日：2000-11-17
申请人： RECKITT BENCKISER HEALTHCARE , CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
发明人： CHAPLEO CHRISTOPHER BOURNE , MCCORMACK KEITH , VAREY NICOLAS CALVERT
IPC分类号： A61K9/02 , A61K9/00 , A61K9/08 , A61K9/20 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , A61P25/04
CPC分类号： A61K9/0019 , A61K9/0056 , A61K9/006 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/26 , Y10S514/811 , Y10S514/812 , A61K2300/00
摘要： An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1, whereby the analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
摘要翻译：以肠胃外单位剂量形式或以适合于通过粘膜递送的单位剂量形式的镇痛组合物，其包含少于实现疼痛缓解所需的临床剂量的丁丙诺啡和一定量的纳洛酮，使得丁丙诺啡的重量比纳洛酮的量范围为12.5:1至27.5:1，或纳曲酮或纳美芬的量，使得丁丙诺啡与纳曲酮或纳美芬的重量比在12.5:1至22.5:1的范围内，由此丁丙诺啡的镇痛作用被纳洛酮，纳曲酮或纳美芬的低剂量加强。

10. 发明申请

WO01013921A1 TRIPLE DRUG THERAPY FOR THE TREATMENT OF NARCOTIC AND ALCOHOL WITHDRAWAL SYMPTOMS 审中-公开
标题翻译：治疗难治性和酒精性抽搐症状的三联药物治疗
公开(公告)号：WO01013921A1
公开(公告)日：2001-03-01
申请号：PCT/US2000/021580
申请日：2000-08-08
IPC分类号： A61K31/135 , A61K31/137 , A61K31/155 , A61K31/165 , A61K31/192 , A61K31/195 , A61K31/415 , A61K31/4168 , A61K31/421 , A61K31/438 , A61K31/4458 , A61K31/495 , A61K31/522 , A61K31/55 , A61K31/5513
CPC分类号： A61K31/522 , A61K31/135 , A61K31/137 , A61K31/155 , A61K31/165 , A61K31/192 , A61K31/195 , A61K31/415 , A61K31/4168 , A61K31/421 , A61K31/438 , A61K31/4458 , A61K31/495 , A61K31/55 , A61K31/5513 , Y10S514/811 , A61K2300/00
摘要： A triple drug, pharmaceutical kit, composition, and method of treatment containing a combination of effective amounts of at least one anxiolytic agent, at least one centrally acting alpha antiadrenergic agent, and at least one central nervous system stimulant for the reduction or prevention of alcohol and narcotic withdrawal side effects of dizziness, drowsiness, depression, lethargy, orthostatic hypotension, weakness in the extremities, and difficulty in being mobile, caused by therapeutic agents utilized for the treatment of alcohol or narcotic withdrawals symptoms in patients overcoming alcohol or narcotic addiction.
摘要翻译：包含有效量的至少一种抗焦虑剂，至少一种中枢作用的α抗肾上腺作用剂和至少一种用于还原或预防酒精的中枢神经系统兴奋剂的组合的三联药物，药物试剂盒，组合物和治疗方法以及用于治疗酒精或麻醉药物成瘾的患者用于治疗酒精或麻醉药提取症状的治疗剂引起的眩晕，嗜睡，抑郁，嗜睡，直立性低血压，四肢无力以及难以移动的麻醉戒断副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式